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Abstract
The restriction of the Human Immunodeficiency Virus (HIV) infection in quiescent CD4+ T cells has been an area of
active investigation. Early studies have suggested that this T cell subset is refractory to infection by the virus.
Subsequently it was demonstrated that quiescent cells could be infected at low levels; nevertheless these
observations supported the earlier assertions of debilitating defects in the viral life cycle. This phenomenon raised
hopes that identification of the block in quiescent cells could lead to the development of new therapies against
HIV. As limiting levels of raw cellular factors such as nucleotides did not account for the block to infection, a
number of groups pursued the identification of cellular proteins whose presence or absence may impact the
permissiveness of quiescent T cells to HIV infection. A series of studies in the past few years have identified a
number of host factors implicated in the block to infection. In this review, we will present the progress made, other
avenues of investigation and the potential impact these studies have in the development of more effective
therapies against HIV.
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Introduction
Quiescence is a unique feature of our immune system as
T lymphocytes can remain at a non-dividing state for
prolonged periods of time. The majority of circulating T
cells in blood are in a quiescent state. This is character-
ized by low metabolic rates, low levels of transcription,
small size and very long periods of survival [1,2]. It was
long thought that T cell quiescence was a default state.
A recent series of studies reversed this notion as they
demonstrated that a number of transcription factors ac-
tively maintained this state [1-10]. To this date, LKLF
[3,4,8], FOXO1,3 and 4 [7,11-18], and Tob [6,10,19,20]
have been identified as key factors that maintain T cell
quiescence . Loss of expression of any of the above pro-
teins resulted in aberrant T cell proliferation, cellular
damage due to higher metabolism, and cell death. CD4+
T cell quiescence and its effect on HIV infection has
been a topic of intense investigation as early studies in-
dicated that they are resistant to HIV infection. As a re-
sult a strong interest was developed to identify cellular
factors that mediate this block and can potentially be the
basis for effective therapeutic approaches against HIV.
None of the factors regulating T cell quiescence have
been implicated in influencing HIV infection.
In this review, we will discuss the steps of the viral life
cycle inhibited in quiescent CD4+ T cells, the factors in-
volved and the impact these studies have in understand-
ing HIV infection in quiescent T cells as well as the
development of better targets against the virus.
HIV replication is defective in quiescent CD4+ T cells
For the past two decades, the infection of quiescent CD4
T cells by HIV has been an area of intense investigation.
Unlike other retroviruses, HIV replication is not dependent
on cell cycle. Nevertheless, HIV and other lentiviruses
more efficiently infect non-dividing cells and establish a
latent infection [21-23]. While early reports supported the
notion that only pre-activated T cells can be infected by
HIV [24-26], subsequent studies showed that quiescent
T cells could be infected by the virus [27-30]. Yet, key
differences arose relating to the degree and levels of infec-
tion efficiency.
On the one hand it was shown that HIV viral entry
and initiation of reverse transcription were not affected.
However, completion of reverse transcription was ineffi-
cient resulting in the accumulation of labile, intermedi-
ate viral cDNA species [28,29]. Rescue of infection was
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possible with stimulation but it was temporally sensitive
as production of viral progeny decreased at later reacti-
vation timepoints [29]. Additional work focusing on the
CD25- (non-activated) and CD25+ (activated) T cell
populations lent more support to the notion that quies-
cent T cells are resistant to HIV infection [31-33]. In the
absence of any stimulation, HIV infection of CD25- T
cells failed while that of CD25+ was successful. Further-
more, when total human peripheral blood monocytes
were infected, the CD25- population did carry viral
cDNA suggesting either bystander activation of the
non-activated population or more efficient infection via
cell-cell contact. Finally, Tang and colleagues further
supported the above observations by demonstrating that
infection of quiescent cells with HIV did not result in
the production of virus [34].
On the other hand, other studies showed that HIV in-
fection of quiescent T cells could be productive. More
specifically, they demonstrated that the viral cDNA was
fully reverse transcribed and stably localized in the cyto-
sol. This linear cDNA following T cell activation would
then integrate and result in the production of viral pro-
geny [27,30]. Thus, the block was not seen at the early
stages of infection such as reverse transcription but later
either in nuclear transport or integration [27,30]. How-
ever, the key conclusion from these studies was that the
block could be easily alleviated at any time after infec-
tion with T cell activation, a notion not shared by the
studies outlined above [29].
Despite the divergent opinions, this early work clearly
demonstrated that the life cycle of HIV in quiescent
CD4+ T cells was quite distinct from that of activated T
cells and warranted further investigation. As technolo-
gies evolved, our knowledge was further expanded in
regards to the characteristics of the HIV life cycle in qui-
escent T cells. Studies by Korin et.al utilized a cell cycle
progression assay that could assess the levels of both
RNA and DNA synthesis and demonstrated that non-
dividing T cells can be classified into two categories: (1)
cells in the Go/G1a phase which is characterized by
undetectable levels of DNA and RNA synthesis (truly
quiescent) and (2) cells in the G1b phase which is char-
acterized by high levels of RNA expression but not DNA
[35]. Following infection of these two sub-populations of
non-dividing T cells, it was shown that cells in the G1b
stage were susceptible to infection while the truly quies-
cent Go/G1a were resistant [35]. Thus, the data did lend
a justification for the disagreement raised in the earlier
studies. It would have been possible that the rescue seen
after stimulation was due to the fact that G1b phase cells
were infected. More importantly, this study underscored
the fact that partly activated but non-dividing T cells can
be productively infected by HIV and that quiescent T
cells are indeed resistant to infection.
Overall these early studies established that HIV repli-
cation in quiescent cells is defective. As new and more
sensitive technologies developed, groups were able to
further dissect and examine in more detail the stages of
the viral life cycle that is impacted in quiescent T cells.
These studies were more focused on the events leading
up to including integration with a growing number in-
terested in post-integration events.
Pre-integration blocks to HIV infection in quiescent T cells
A series of studies using more sensitive PCR techniques
further supported the opinion that quiescent T cells
were resistant to infection and shed some more light on
what stages of the HIV life cycle were impacted. The
Siliciano group, using a linker-mediated PCR assay, de-
termined that in quiescent T cells reverse transcription
occurred at a slower rate, 2–3 days, and produced viral
cDNA with a half life of a approximately a day [36]. Des-
pite the formation of full-length viral cDNA, the infec-
tion was not productive. In a follow up study, the same
group found that the linear non-integrated cDNA was
integration competent [37]. Thus, these studies sup-
ported and further characterized the presence of labile
viral cDNA that was not able to support a productive
HIV infection.
Moreover, the development of a sensitive and quantita-
tive assay allowed for the detection of low levels of inte-
gration in HIV infected cells [38] and proved to be very
useful in the study of HIV infection in quiescent T cells.
Using this assay the O’Doherty group demonstrated that
quiescent CD4+ T cells were infectable by HIV resulting in
accumulation of viral cDNA over a three-day period and
subsequent integration [39-41]. Furthermore, the authors
were able to induce expression of virus following stimula-
tion with IL-7 and anti-CD3/anti-CD28. These studies
demonstrated that a productive and latent infection could
be established in quiescent cells. However, despite these
promising results, the major deficiencies previously seen
in quiescent T cells, still persisted and potentially were
masked by the use of spinoculation [42] as a method
of infection.
Studies done by our group using quantitative real time
PCR assays and the integration assay developed by the
O’Doherty group analyzed in more detail the kinetics of
HIV infection in quiescent CD4 T cells and compared
them with that of stimulated T cells [43]. Based on our
results, we did not observe any defects on viral entry.
However, we did see a significant difference in reverse
transcription. Unlike the earlier studies, initiation of re-
verse transcription was severely decreased (30-fold
lower) in quiescent T cells. Interestingly, there was com-
pletion of reverse transcription that was delayed by 16 -
hours. The newly synthesized viral cDNA did integrate
in quiescent cells with efficiency similar to that of
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activated T cells. However, the process was completed
24 hours later than that seen in activated T cells. The in-
tegrated provirus found in quiescent T cells did express
low levels of multiply spliced viral mRNA, however this
did not translate into the expression of detectable viral
protein. Interestingly, activation immediately after infec-
tion did not rescue this inefficient infection process in
quiescent T cells [43]. The results from our studies re-
vealed and pointed to debilitating blocks in the early
stages of the viral life cycle as well as delays leading up
to viral integration.
HIV integration and viral expression defects in quiescent
T cells
The finding that there is proviral DNA in quiescent T
cells raised the possibility that quiescent T cells can be a
reservoir that could support a spreading infection. Inte-
grated virus was previously found in resting cells of HIV
infected patients but this was attributed to the infection
of previously activated T cells that returned to a resting
state [44]. Furthermore, the presence viral mRNA in our
studies but the lack of detectable viral protein [43] raised
the possibility that HIV integration site selection in qui-
escent T cells may be distinct from activated ones. Since
T cell quiescence is an actively maintained state and
HIV preferentially integrates into transcriptionally active
units, it would be inferred that a distinct distribution of
integration sites could explain our observations. Others
and we examined integration site selection in quiescent
CD4+ T cells [45,46]. Based on our data, integration in
both activated and quiescent CD4+ T cells occurred in
transcriptionally active units such as housekeeping genes
that were not affected by cell state [45]. The orientation
of integrants between the two cell types was similar as
well as the chromosomal locations. Yet, despite the ob-
served similarities, proviral DNA in quiescent cells
exhibited higher levels of abnormal LTR-host junctions
[45]. Furthermore, we observed higher levels of 2-LTR
circles with both normal and abnormal junctions [45].
These patterns suggest that the delays prior to integra-
tion had a severe detrimental effect on the ends of the
viral cDNA. On the other hand, in the studies by Brady
et.al, HIV integration patterns were somewhat different
between stimulated and quiescent T cells [46]. HIV inte-
grated in less transcriptionally active regions in quies-
cent cells when compared to stimulated cells, but the
observed differences were modest. Yet, despite the dif-
fering conclusions, both studies identified additional po-
tential blocks to HIV infection: (i) LTR attrition that can
lead to the integration of defective virions and (ii) inte-
gration into transcriptionally repressed regions.
The integration site analysis outlined above however
suggested that quiescent T cells might be a source of
viral release. To this date, only a handful of studies have
examined the post integration events of the HIV life
cycle in quiescent cells and in the absence of any stimu-
lation. As quiescent T cells are transcriptionally less ac-
tive and given the defects in the early stages of infection
resulting in mutations of the viral cDNA as well as the
potential integration into transcriptionally repressive re-
gions, spontaneous viral release in HIV infected quies-
cent T cells can also be impaired. Recently studies using
the SIV rhesus macaque model suggested that infected
resting T cells can spontaneously release virions [47].
However, the transcriptional state of these cells was not
fully examined. Our data as well as recent work have
shown that multiply spliced tat/rev mRNA are lower
in HIV infected quiescent and resting CD4 T cells
[43,48-51]. This coupled with data from HIV patients on
HAART that show elevated levels of unspliced viral
mRNA compared to spliced would suggest that defects
in splicing can impact the release of virions from quies-
cent T cells [48,52-54]. Furthermore, low levels of multi-
ply spliced HIV RNA would result in lower levels of Tat
protein as it has been shown to play a crucial role in
transcriptional elongation [55-62] and recently in RNA
splicing [63]. Such an outcome could have detrimental
effects in the generation of higher levels of multiply
spliced viral RNA. Yet, even if there is production of ad-
equate levels of multiply spliced HIV RNA in quiescent
T cells, this is further blocked by reduced nuclear export.
This is due to the low levels of the polypyrimidine tract
binding protein (PTB) in resting T cells. Low levels of
PTB results in nuclear retention of multiply spliced viral
RNA thus limiting the production of virions [49,51].
Despite these observed post-integration defects, recent
work by Pace and colleagues demonstrated that there is
observable but low Gag expression in HIV infected rest-
ing T cells [50]. However, this expression of Gag could
not support a spreading infection, as the levels of Env
protein were very low.
Restriction factors
While the above studies identified and further refined
the stages of HIV life cycle impacted in quiescent T cells,
they did not address the mechanisms behind the block.
As quiescent T cells are characterized by low transcrip-
tional and metabolic activity, it was reasonable to infer
that the lack of cellular substrates or raw materials can
have a detrimental effect on viral replication. While pre-
treatment of quiescent T cells with nucleosides improved
reverse transcription in these cells, it failed to rescue in-
fection [64,65]. This suggested that the presence of in-
hibitory factors or the absence of other supportive
processes were responsible for this phenotype.
A number of restriction factors against HIV-1 have been
identified over the years such as APOBEC3G [66-80],
TRIM5 [81-94], tetherin [95-105], MOV10 [106-109] and
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recently micro RNAs [110-114]. However, the focus of this
review will be on the restriction factors uniquely identified
in quiescent CD4+ T cells that may be responsible for the
observed block to HIV-1 infection (Figure 1).
a. Murr1
Murr1 is involved in copper regulation and inhibits
NFκB activity. This inhibition is mediated by
blocking proteosomal degradation of IκB resulting in
decreased NFκB activity [115]. Studies by Ganesh
and colleagues found that the protein is highly
expressed in T cells [115]. This in conjunction with
the role of NFκB in HIV expression made this a
strong candidate for a host restriction factor.
Through siRNA-mediated knockdown, the authors
demonstrated that downregulation of Murr1 resulted
in increased Gag expression suggesting the Murr1
may regulate HIV infection in quiescent CD4+ T cells.
However, the method of siRNA delivery,
nucelofection, even though it did not perturb the
activation state of quiescent cells (based on T cell
activation marker expression CD25, CD69 and HLA-
DR), it may have facilitated infection. While these
studies were quite interesting, there was no follow-up
work performed to further elucidate the role of
this protein.
b. JNK and Pin1
Recent studies highlighted the lack of a cellular
protein rather than the presence of a restriction
factor as a potential block to HIV infection in
quiescent T cells. More specifically, c-Jun N-
terminal kinase (JNK) phosphorylates viral integrase,
which in turn interacts with the peptidyl prolyl-
isomerase enzyme Pin1 causing a conformational
change in integrase [116]. This combined effect
increases the stability of integrase allowing for viral
integration to occur. In these studies quiescent T
cells were found not to express JNK, thus
ameriolating the role of Pin1 in facilitating HIV
intgration [116]. These results lend support to
earlier studies demonstrating the presence of
preintegrated viral cDNA in resting cells that can act
as an inducible reservoir [27,30]. However, these
studies did not address the major defects identified
by us and others in the early stages of the HIV life
cycle as well as the fact that the efficiency of HIV
integration in quiescent cells is similar to that of
activated cells [39,43,45,46].
c. Glut1
Glut1 has recently been implicated as a potential
cellular factor that could facilitate HIV infection.
Like JNK and Pin1, the absence of this protein
seems to impact HIV infection [117]. Interestingly,
its role is linked to the metabolic processes of T
cells. More specifically, Glut1 is a major glucose
transporter found in both mature T cells and
thymocytes [117]. Protein expression is upregulated
by IL-7 treatment or conventional T cell activation.
Figure 1 The HIV life cycle in quiescent CD4+ T cells. The illustration outlines the major steps in HIV life cycle and the protein factors that are
implicated in the observed block. The crossed proteins comprise factors whose lack of expression potentially ameliorates HIV infection.
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When Glut expression was knockdown in activated
T cells, it resulted in decreased HIV infection of
these cells[117]. Expression levels of the protein
were further correlated with permissiveness to HIV
infection as double positive thymocytes expressing
high levels of Glut1 were more likely to be infected
by HIV than their low expressing counterparts
[117]. This study is quite intriguing as it is the first
one linking cell metabolism to HIV replication.
depolymerization factor
d. Cytoskeleton
The cytoskeleton has been shown to have a key role in
HIV replication [118]. The cell structure plays a key
role in cell shape, motility, organelle organization and
intracellular trafficking [118]. This section involves
multiple factors that have been recently identified to
facilitate or block HIV infection. Early work showed
that the HIV reverse transcription complex interacted
with actin and disruption of the interaction resulted in
blocking infection [119]. These studies suggested that
the cytoskeleton was crucial for a productive HIV
infection. Subsequent studies explored the molecular
mechanisms of this phenomenon. More specifically,
Yoder and colleagues showed that cross linking of
CXCR4, one of the co-receptors for the virus, results
in activation of cofilin, an actin that allows for HIV to
rearrange actin and, consequently, facilitate infection
[120]. This was further supported by patient studies
showing that resting T cells isolated from HIV
infected individuals had elevated levels of active cofilin
thus facilitating the spread of infection [121]. In
addition to CXCR4, crosslinking of CCR7, CXCR3,
and CCR6 have been shown to activate cofilin and
mediate the establishment of a latent HIV infection in
resting T cells [122]. However, cofilin is not the sole
factor involved in the interplay between HIV and
actin. LIM domain kinase 1 (LIMK1), which
phosphorylates cofilin and inactivates it, becomes
activated following cross-linking of gp120 and CXCR4
[123]. This leads to actin polymerization and
stabilization of the CD4/CXCR4 cluster allowing for
efficient viral entry and uncoating. The stable complex
then activates cofilin to further facilitate infection.
This pathway was recently shown to be disrupted by
the N-terminal fragment of Slit2 a secreted
glycoprotein and reversed the HIV mediated changes
in actin thus inhibiting infection [124]. These studies
underscore the importance of cytoskeleton in HIV
infection and have become an exciting area of HIV
research as they can lead to the development of new
therapies against the virus.
e. SAMDH1
The Sterile Alpha Motif (SAM) domain and HD
domain-containing protein 1 (SAMHD1) has been
recently identified as a potential restriction factor in
quiescent T cells. SAMHD1, like APOBEC3G, seems
to target the early stages of the HIV life cycle more
specifically reverse transcription. SAMHD1 is mutated
in a subset of patients suffering from the Aicardi-
Goutieres syndrome (AGS), an early-onset
encephalopathy that mimics a congenital infection
and is associated with increased levels of IFN-
.alpha; production [125]. Studies suggested that the
protein may be involved in negatively regulating
innate immune responses [125]. With regards to HIV
restriction, studies showed that SAMHD1 mediated
the restriction to HIV infection in dendritic cells and
monocytes [126-128]. The observed restriction of
SAMHD1 was alleviated by the lentiviral protein Vpx,
which is expressed in SIV[127,129]. When Vpx, a
relative of Vpr the viral accessory protein expressed in
HIV-1, was introduced into macrophages and
monocyte derived dendritic cells, it significantly
enhanced their infection by HIV [130-132]. Additional
studies revealed that SAMHD1 is a strong dGTP
triphosphohydrolase, thus impacting total nucleotide
pools in cells [133,134]. By depleting these pools
SAMHD1 inhibits reverse transcription thus
restricting HIV replication [135].
While a number of studies employed gene
knockdown to further elucidate the role of
SAMHD1 and other restriction factors in HIV
infection, the use of cell samples from AGS patients
has proven particularly beneficial as it eliminated the
variable of cell manipulation. Monocytes and
dendritic cells from AGS patients were susceptible
to HIV infection [127,128]. With respect to
quiescent T cells, two studies have independently
shown that the protein is abundantly expressed in
them [136,137]. Both the SAMDH1 depleted and
AGS patient derived CD4 T cells demonstrated
improved HIV infection due to increased reverse
transcription [136,137]. However, the expression of
viral progeny was still defective in quiescent cells as
suggested by both studies. In addition, even though
SAMHD1 is also highly expressed in activated T
cells, its inhibitory effects are only seen in quiescent
T cells [127,135,136]. Thus, the combination of both
limiting endogenous pools of nucleotides in
quiescent T cells and the presence of SAMHD1 have
a combined inhibitory effect on viral replication.
As the field further explores the role of SAMHD1 it
is clear that the protein limits the available
nucleotide pools in quiescent cells thus restricting
efficient reverse transcription. However, as previous
studies have shown, a mere addition of nucleosides
while improving reverse transcription does not
remedy the block seen in quiescent T cells [64,65].
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Conclusions
In conclusion, the mechanisms and/or cellular factors
mediating the block in the HIV infection of quiescent
CD4 T cell are not fully understood yet. While a number
of cellular factors have been implicated, it is clear that
the blocking effect to HIV infection is mediated by mul-
tiple events due to the physiology of quiescent T cells.
Cellular size, transcriptional and metabolic activities are
all important cell functions that are used by intracellular
parasites such as viruses to successfully infect and repli-
cate into the host cells.
Based on the early and subsequent work, the char-
acterization of the HIV life cycle in quiescent T cells
strongly indicate that the major impact to infection oc-
curs very early, immediately following viral entry at the
initiation of reverse transcription. While limited raw ma-
terials such as nucleotides impacted by both the nature
of quiescent cells and SAMHD1 can result in decreased
levels of reverse transcription, it is clear that down-
stream events prior to integration or even at integration
are quite important. In addition, another process that is
widely bypassed due to technical challenges, uncoating
can be impacted in quiescent cells and be detrimental to
infection [138,139].
Therefore, further studies are needed to understand
the block in quiescent T cells. To this date, based
on what we know and the nature of cellular factors iden-
tified, it is not clear how the mechanisms of resistance
in quiescent cells can translate into future therapies.
Nevertheless, these studies will allow us to better under-
stand the relationship between HIV and it various target
cells which can ultimately can lead to more effective
interventions.
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